LILLY FDA Approval NDA 020815

NDA 020815

LILLY

FDA Drug Application

Application #020815

Documents

Letter2007-09-25
Label1999-09-30
Review1998-11-24
Letter1999-09-30
Letter2007-07-24
Label2007-07-24
Review2009-12-03
Review1999-09-30
Medication Guide2009-11-18
Label2018-07-05
Letter2018-07-06

Application Sponsors

NDA 020815LILLY

Marketing Status

Prescription001

Application Products

001TABLET;ORAL60MG1EVISTARALOXIFENE HYDROCHLORIDE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP1997-12-09PRIORITY
EFFICACY; EfficacySUPPL2AP1998-11-24STANDARD
EFFICACY; EfficacySUPPL3AP1999-09-30PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL4AP2000-05-09PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL5AP2000-06-23PRIORITY
LABELING; LabelingSUPPL6AP2000-06-27STANDARD
LABELING; LabelingSUPPL7AP2000-12-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL8AP2001-07-02PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL9AP2002-01-17PRIORITY
LABELING; LabelingSUPPL10AP2002-06-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL11AP2002-05-07PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL12AP2002-12-24PRIORITY
LABELING; LabelingSUPPL18AP2007-07-17STANDARD
LABELING; LabelingSUPPL25AP2007-09-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL32AP2016-01-11PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL33AP2016-01-25PRIORITY
LABELING; LabelingSUPPL34AP2018-06-27STANDARD

Submissions Property Types

SUPPL1Null0
SUPPL4Null0
SUPPL5Null0
SUPPL8Null0
SUPPL9Null0
SUPPL11Null0
SUPPL12Null0
SUPPL32Null0
SUPPL33Null0
SUPPL34Null15

TE Codes

001PrescriptionAB

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 20815
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.